Fox Chase Cancer Center researchers identify novel target for detecting ovarian cancer in blood

September 15, 2004

PHILADELPHIA (September 10, 2004)--Fox Chase Cancer Center researchers have found a new way to detect ovarian cancer in the blood. Reported in the Sept. 15, 2004, issue of Cancer Research, the new method targets hypermethylation--one mechanism used by cancer cells to turn off genes that protect against tumor development.

When these tumor-suppressor genes are inactivated by hypermethylation, they cannot do their job, which then allows cancer cells to develop. This research marks the first time hypermethylation has been examined for the detection of ovarian cancer.

Fox Chase molecular biologist Paul Cairns, Ph.D., and his colleagues tested for hypermethylation of BRCA1 and RASSF1A, two genes strongly associated with ovarian cancer.

"In normal cells, BRCA1 and RASSF1A are unmethylated, meaning they are able to do their job. We found these genes to be frequently hypermethylated in the blood and peritoneal fluid from patients with ovarian cancer," explained Cairns.

Tumor samples, preoperative blood and peritoneal fluid DNA were obtained and matched from 50 patients with ovarian or primary peritoneal cancer. The blood from 20 healthy age-matched women, normal ovary tissue from 10 women, and tissue, blood and peritoneal fluid from 10 women with benign ovarian cysts were used for controls.

Thirty-four of the 50 tumors (68 percent) showed hypermethylation of one or both genes. The remaining 16 tumor samples, which did not show hypermethylation for RASSF1A or BRCA1, had hypermethylated forms of other tumor-suppressor genes: APC, p14, p16 and DAP (death-associated protein-kinases), which provided a target for screening.

An identical pattern of gene hypermethylation was found in the matched blood DNA from 41 of 50 patients (82 percent sensitivity), including 13 of 17 cases of stage I disease. No hypermethylation was observed in the non-cancerous tissue, peritoneal fluid or blood from control samples (100 percent specificity).

"We were keenly interested in the potential of hypermethylation for the detection of early ovarian tumors," said Cairns, "so we tested an additional 21 stage I tumor DNA samples." Twenty of the 21 showed hypermethylation of at least one of the six genes in the panel.

"Hypermethylation is a common event in these tumors and appears to happen relatively early because we found it in early-stage cancers," said Mitchell Edelson, M.D., a gynecological oncologist in the department of surgical oncology at Fox Chase and a co-author of the study.

"What's encouraging about this research is that there were no false-positive results. A gene negative for hypermethylation in the tumor DNA was always negative in the matched serum or peritoneal fluid DNA.

"There is no other obvious body fluid available for ovarian cancer testing except the blood," Edelson added. "In the past couple of years, we have seen detection attempts with proteomics and now with this method. It is encouraging to see so much activity regarding one of the most feared diseases for women."

The potential application of this finding could be significant because there is no reliable screening method available for ovarian cancer. Most women are diagnosed with late-stage disease after developing symptoms. The cure rate for women with advanced ovarian cancer is low, but doctors are often successful in treating early-stage disease.

"It would appear that hypermethylation is a very specific marker for this disease, and if confirmed in larger studies, methylation may be useful in ovarian cancer diagnosis," said Cairns.

In earlier research, Cairns and his colleagues have demonstrated the ability to detect prostate and kidney cancer by targeting hypermethylation.
-end-
This research was supported by a National Cancer Institute grant to Fox Chase for a Specialized Program of Research Excellence in ovarian cancer, the Pennsylvania Department of Health Ovarian Cancer Program and the Ovarian Cancer Research Fund.

Fox Chase Cancer Center was founded in 1904 in Philadelphia as the nation's first cancer hospital. In 1974, Fox Chase became one of the first institutions designated as a National Cancer Institute Comprehensive Cancer Center. Fox Chase conducts basic, clinical, population and translational research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu or call 1-888-FOX CHASE.

Fox Chase Cancer Center

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.